United Kingdom· GB-APID-11937811000001106
Cardioxane 500mg powder for solution for infusion vials
A dexrazoxane product containing dexrazoxane, registered in United Kingdom by CNX Therapeutics Ltd. The same ATC class is registered in 15 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Dexrazoxane is registered in 15 of 19 countries.
Countries holding a registration under ATC V03AF02 (dexrazoxane), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Dexrazoxane · ATC V03AF02
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of dexrazoxane costs, country by country.
Normalised to the WHO defined daily dose (1.5 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Dexrazoxane · price per daily dose (1.5 g)
USD · FX 28 Sept 2026
- FI Finland$8.88
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Dexrazoxane
- Manufacturer
- CNX Therapeutics Ltd
- Country
- United Kingdom (GB)
- ATC code
- V03AF02
- ATC class
- Dexrazoxane
- Defined daily dose
- 1.5 g, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 3
- gtin8714023000603
- gtin5060229220103
- gtin05060475950403
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
8 interactions on record for dexrazoxane.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dexrazoxane · interactions on record
8 records
- 2 severe
- 6 moderate
Most severe, free to view
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- Lactobacillus acidophilusJ07AX04moderate
- DoxorubicinL01DB01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Dexrazoxane in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainCARDIOXANE 500 mg POLVO PARA SOLUCION PARA PERFUSIONCnx Therapeutics Ireland Limited
- FinlandCardioxaneNovartis Finland Oy
- PolandCardioxaneClinigen Healthcare B.V.
- United StatesDexrazoxaneHikma Pharmaceuticals USA Inc.
- GermanyCardioxaneCnx Therapeutics Ireland Limited
- FranceCARDIOXANE 500 mg, poudre pour solution pour perfusionCNX THERAPEUTICS IRELAND LIMITED (IRLANDE)
- NetherlandsCardioxane 500 mg poeder voor oplossing voor infusieCNX Therapeutics Ireland Limited
- SwedenSavene 20 mg/ml Pulver till koncentrat och vätska till infusionsvätska, lösningCNX Therapeutics Ireland Ltd
Authorised across Europe · EMA
The same active substance is authorised in 14 EEA countries. Names it is sold under:
- Austria · Cyrdanax
- Czechia · Cyrdanax
- Germany · Cardioxane, Cyrdanax
- Spain · Cardioxane
- France · Cardioxane, Cyrdanax
- Hungary · Cyrdanax
- Iceland · Savene
- Italy · Cardioxane
- Liechtenstein · Savene
- Netherlands · Cardioxane
- Norway · Savene
- Poland · Cyrdanax
- Romania · Cyrdanax
- Slovakia · Cyrdanax
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c7e317e5-3911-41e2-9514-5cd5489454c2 GET /v1/drugs/c7e317e5-3911-41e2-9514-5cd5489454c2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "11937811000001106",
"desc": "Cardioxane 500mg powder for solution for infusion vials (CNX Therapeutics Ltd)",
"form": "Powder for solution for infusion",
"vpid": "11937411000001109",
"source": "dmd",
"vtm_id": "775518007",
"strength": "500 mg",
"substance": "Dexrazoxane",
"ingredient": "Dexrazoxane",
"supplier_code": "26657611000001108"
}See everything about dexrazoxane.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.